Overview
Investment Type
Venture Capital
Funds raised 1
| Date | Fund size | Announcement |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 3, 2013 | Intranasal drug delivery disruptor OptiNose signs licensing deal for migraine treatment | A company that’s poised to disrupt the nasal drug delivery market has signed a licensing deal with Avanir Pharmaceuticals (Nasdaq: AVNR) valued at $110 million. OptiNose’s drug delivery system in Phase 3 development to treat migraine headac... |
| Mar 16, 2011 | FDA panel: Novocure’s brain tumor device improves quality of life but not survival rate | A revolutionary treatment for a deadly form of brain cancer failed to show a significant increase in the overall survivability rate when measured against chemotherapy, according to an FDA reviewers document posted on the agency’s web site. ... |
| Mar 14, 2011 | Cancer treatment: Novocure’s brain tumor device goes before FDA panel | A new treatment for a deadly form of brain cancer will get its date before an FDA panel this week, as NovoCure, a privately-held Israeli company, brings its NovoTTF-100A device before the agency’s neurological devices panel March 17. The No... |
| Jun 7, 2010 | Avista Capital Partners Commits $48.5 Million to Optinose to Develop an Innovative Nasal Drug Delivery Technology Slated to Begin Phase III Trials | New York, NY, June 7, 2010 – Avista Capital Partners (“Avista”), a leading private equity firm, today announced it has committed to invest $48.5 million in OptiNose (“OptiNose” or “the Company”). OptiNose has developed an innovative nasal d... |
| Mar 9, 2010 | WFD Ventures raises $116M for second investment fund | Portfolio companies include cancer device developer Novocure Ltd. of Israel, diagnostic products maker Bioscale of Cambridge, Mass. and cardiac device firm Imacor LLC of Uniondale, N.Y. WFD’s latest fundraise comes from seven investors, acc... |
| WFD Ventures raises $116M for second investment fund | Health care investor WFD Ventures has raised $116 million for its second fund, according to a Securities and Exchange Commission filing. WFD typically invests between $2 million and $15 million in therapeutic, diagnostic and drug-delivery c... | |
| Intranasal drug delivery disruptor OptiNose signs licensing deal for migraine treatment | A company that’s poised to disrupt the nasal drug delivery market has signed a licensing deal with Avanir Pharmaceuticals (Nasdaq: AVNR) valued at $110 million. OptiNose’s drug delivery system in Phase 3 development to treat migraine headac... |
Reviews 0
FAQ about WFD Ventures
What funds has WFD Ventures raised?
WFD Ventures has announced 1 fund on Parsers VC.
What has the press written about WFD Ventures?
Parsers VC has collected 8 articles mentioning WFD Ventures, among them “Intranasal drug delivery disruptor OptiNose signs licensing deal for migraine treatment” (Jul 3, 2013) and “FDA panel: Novocure’s brain tumor device improves quality of life but not survival rate” (Mar 16, 2011).
Is WFD Ventures still active?
WFD Ventures is probably closed: its latest activity on Parsers VC dates from Oct 7, 2015.